Nano-X Imaging (NASDAQ:NNOX) Director Dan Suesskind Purchases 50,000 Shares

Nano-X Imaging Ltd. (NASDAQ:NNOX) Director Dan Suesskind bought 50,000 shares of the business’s stock in a transaction dated Monday, July 27th. The stock was bought at an average cost of $0.93 per share, for a total transaction of $46,500.00. Following the completion of the purchase, the director owned 50,000 shares of the company’s stock, valued at approximately $46,500. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Nano-X Imaging Price Performance

NNOX opened at $0.88 on Thursday. The stock has a 50-day moving average price of $1.45 and a 200-day moving average price of $2.06. The firm has a market cap of $61.05 million, a PE ratio of -0.56 and a beta of 1.24. Nano-X Imaging Ltd. has a 1 year low of $0.73 and a 1 year high of $5.08.

Nano-X Imaging (NASDAQ:NNOX) last announced its quarterly earnings results on Thursday, June 25th. The company reported ($0.16) earnings per share (EPS) for the quarter. The firm had revenue of $4.31 million during the quarter. Nano-X Imaging had a negative return on equity of 70.96% and a negative net margin of 716.44%. As a group, sell-side analysts anticipate that Nano-X Imaging Ltd. will post -0.6 EPS for the current year.

Key Headlines Impacting Nano-X Imaging

Here are the key news stories impacting Nano-X Imaging this week:

• Positive Sentiment: CEO Erez Meltzer purchased 36,000 NNOX shares at an average price of $0.93, investing approximately $33,480. Director Dan S. Suesskind also bought 50,000 shares at the same average price, signaling that insiders may view the depressed valuation as attractive. However, the purchases are relatively small compared with the company’s broader financial and legal risks. CEO insider purchase filing Director insider purchase filing
• Neutral Sentiment: Rosen, Levi & Korsinsky, Faruqi & Faruqi and other firms reminded investors of the August 11 deadline to seek lead-plaintiff status. These notices are largely legal-firm solicitations rather than new operating developments, but their frequency increases visibility around the litigation. Rosen deadline notice Levi and Korsinsky deadline notice
• Negative Sentiment: The class action filed against Nano-X and certain officers alleges that the company failed to disclose rising cash burn and operating expenses before recording a $17.5 million impairment and undertaking manufacturing restructuring. The allegations relate to shares purchased between March 31, 2025 and April 17, 2026, and have not been proven in court. Potential legal costs, reputational damage and uncertainty over the company’s finances are weighing on NNOX. Pomerantz class action announcement

Institutional Trading of Nano-X Imaging

A number of institutional investors have recently made changes to their positions in NNOX. AQR Capital Management LLC purchased a new position in shares of Nano-X Imaging during the first quarter valued at approximately $178,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Nano-X Imaging by 232.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,160,806 shares of the company’s stock valued at $10,793,000 after purchasing an additional 1,510,806 shares during the period. Geode Capital Management LLC boosted its holdings in Nano-X Imaging by 17.5% in the second quarter. Geode Capital Management LLC now owns 810,322 shares of the company’s stock worth $4,189,000 after purchasing an additional 120,460 shares during the last quarter. Cetera Investment Advisers boosted its holdings in Nano-X Imaging by 82.0% in the second quarter. Cetera Investment Advisers now owns 48,056 shares of the company’s stock worth $248,000 after purchasing an additional 21,657 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in Nano-X Imaging by 61.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 65,783 shares of the company’s stock worth $340,000 after purchasing an additional 25,048 shares during the period. Hedge funds and other institutional investors own 21.49% of the company’s stock.

Analyst Ratings Changes

NNOX has been the subject of several analyst reports. D. Boral Capital reissued a “buy” rating and set a $5.00 price target on shares of Nano-X Imaging in a research report on Monday, April 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nano-X Imaging in a research report on Wednesday, July 8th. Alliance Global Partners downgraded Nano-X Imaging from a “buy” rating to a “neutral” rating and cut their target price for the company from $5.00 to $3.00 in a research note on Tuesday, July 7th. Finally, Zacks Research raised Nano-X Imaging from a “strong sell” rating to a “hold” rating in a report on Monday, June 22nd. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $4.00.

About Nano-X Imaging

Nano-X Imaging Ltd. is a medical technology company developing and commercializing a digital X-ray imaging platform designed to lower the cost and increase the accessibility of diagnostic imaging. Its flagship product, the Nanox.ARC, leverages a proprietary micro-electromechanical system (MEMS) based digital X-ray source and advanced image processing software to provide 2D and 3D imaging capabilities on a compact footprint. The system aims to streamline radiology workflows and facilitate point-of-care diagnostics in hospitals, clinics and outpatient settings.

The Nanox.ARC platform integrates a novel cold cathode X-ray source, which enables multiple emission points without the need for rotating anode tubes.